Severe Acute Respiratory Syndrome–Coronavirus-2 Infection and Patients With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy

The coronavirus disease 2019 outbreak is evolving rapidly worldwide. The lungs are the target of the primary infection and patients with lung cancer seem to have a poor prognosis. To our knowledge, this is the first reported investigation of a possible role of interleukin-17 target therapy in patien...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2020-07, Vol.15 (7), p.e101-e103
Main Author: Cafarotti, Stefano
Format: Article
Language:English
Subjects:
Betacoronavirus - drug effects
Betacoronavirus - physiology
Chemokines, CXC - metabolism
Coronavirus Infections - drug therapy
Coronavirus Infections - immunology
COVID-19
Drug Discovery
Humans
IL-17 target therapy
Inflammation - immunology
Interleukin-17 - antagonists & inhibitors
Interleukin-17 - immunology
Letter to the Editor
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - immunology
Molecular Targeted Therapy - methods
Monoclonal antibody
Pandemics
Pneumonia, Viral - drug therapy
Pneumonia, Viral - immunology
Respiratory Distress Syndrome - drug therapy
Respiratory Distress Syndrome - immunology
SARS-CoV-2
Th17 Cells - immunology
Up-Regulation - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The coronavirus disease 2019 outbreak is evolving rapidly worldwide. The lungs are the target of the primary infection and patients with lung cancer seem to have a poor prognosis. To our knowledge, this is the first reported investigation of a possible role of interleukin-17 target therapy in patients with lung cancer and concomitant severe acute respiratory syndrome–coronavirus-2 infection.
ISSN:1556-0864
1556-1380
DOI:10.1016/j.jtho.2020.04.015